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Background: MicroRNA-200c (miR-200c) is one of the short noncoding RNAs that play crucial roles in tumorigenesis
and tumor progression. It also acts as considerable modulator in the process of epithelial-to-mesenchymal transition
(EMT), a cell development regulating process that affects tumor development and metastasis. However, the role of
miR-200c in bladder cancer cells and its mechanism has not been well studied. The purpose of this study was to
determine the potential role of miR-200c in regulating EMT and how it contributed to bladder cancer cells in invasion,
migration and proliferation.
Methods: Real-time reverse transcription-PCR was used to identify and validate the differential expression of MiR-200c
involved in EMT in 4 bladder cancer cell lines and clinical specimens. A list of potential miR-200 direct targets was
identified through the TargetScan database. The precursor of miR-200c was over-expressed in UMUC-3 and T24 cells
using a lentivirus construct, respectively. Protein expression and signaling pathway modulation were validated through
Western blot analysis and confocal microscopy, whereas BMI-1 and E2F3, direct target of miR-200c, were validated by
using the wild-type and mutant 3′-untranslated region BMI-1/E2F3 luciferase reporters.
Results: We demonstrate that MiR-200c is down-regulated in bladder cancer specimens compared with adjacent ones
in the same patient. Luciferase assays showed that the direct down-regulation of BMI-1 and E2F3 were miR-200c-
dependent because mutations in the two putative miR-200c-binding sites have rescued the inhibitory effect.
Over-expression of miR-200c in bladder cancer cells resulted in significantly decreased the capacities of cell invasion,
migration and proliferation. miR-200c over-expression resulted in conspicuous down-regulation of BMI-1and E2F3
expression and in a concomitant increase in E-cadherin levels.
Conclusions: miR-200c appears to control the EMT process through BMI-1 in bladder cancer cells, and it inhibits their
proliferation through down-regulating E2F3. The targets of miR-200c include BMI-1 and E2F3, which are a novel
regulator of EMT and a regulator of proliferation, respectively.
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Bladder cancer is one of the most lethal urological ma-
lignant tumors worldwide [1]. A multistep accumulation
of genetic and epigenetic factors result in uncontrolled
cellular invasion, migration, proliferation, increased cell
survival, and metastatic spread. Although the treatment
of bladder cancer has improved greatly in recent years,* Correspondence: chenhege@hotmail.com; jianjunliulab@163.com
†Equal contributors
Laboratory of Urology, Guangdong Medical College, Zhanjiang 524001,
China
© 2014 Liu et al.; licensee BioMed Central Ltd.
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.the incidence of this disease is gradually increasing. Re-
cent advances in the use of high-throughput methods of
molecular analysis have made it easier to identify genetic
profiles characteristic of distinct tumor types and to
identify targets and pathways that may underlie a par-
ticular clinical behavior; however, systemic chemother-
apy remains palliative and only modestly effective [2].
A biological process known as epithelial-to-mesenchymal
transition (EMT) has been reported as having a role in
tumor invasion, migration and metastasis [3]. EMT is
characterized by losing epithelial cell marker such asThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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expression of mesenchymal proteins including vimentin
[4]. During EMT, down-regulation of E-cadherin induces
epithelial cells undergoing changes in cell morphology and
motility so that they adopt mesenchymal characteristics
[5]. Expression of E-cadherin is controlled by several tran-
scriptional repressors, including Twist, Snail1, Snail2/Slug,
E47, ZEB1/TCF8, and ZEB2/SIP1, which bind to E-boxes
in the E-cadherin promoter [6]. The transcriptional re-
pressors also induce the mesenchymal genes N-cadherin
and Vimentin [7].
MicroRNAs (miRNAs) are noncoding RNAs of ap-
proximately 20–22 nucleotides that function in post-
transcriptional gene regulatory pathways [8]. Alterations
in miRNA expression have been described in many
different human tumors, and numerous studies have
demonstrated that miRNAs function as key pathogenic
components, impacting cancer cell growth, survival, and
the capacity to metastasize [9-14]. Recent studies have
shown that ZEB1 and ZEB2 are direct targets of the
miR-200 family in human breast cancer cells (MDA-
MB-231), canine kidney cells (MDCK), murine models,
and a NCI-60 panel of cell lines [15-17]. The down-
regulation of ZEB1 and ZEB2 increased E-cadherin ex-
pression; in contrast, loss of miR-200, which occurs in
many different human cancers, including breast cancer
[18], ovarian cancer [19], prostate cancer [20], and endo-
metrial carcinoma [21], results in increased ZEB1/ZEB2
and repression of E-cadherin [16,22-24]. This latter change
is coincident with more aggressive biological behavior in
cancer (increased invasion and migration) [16,18,24,25].
Hundreds of miRNAs are encoded in the human genome,
with an estimated 30% of mRNAs possessing conserved
miRNA-binding sites, suggesting that miRNA-based regu-
lation is an integral component of the global gene expres-
sion program [26].
The Polycomb group (PcG) of proteins comprises an
important class of transcriptional repressors that orches-
trate changes in chromatin structure to regulate gene ac-
tivity, and many of the PcG proteins demonstrate altered
expression in human cancers [27,28]. BMI-1 is a PcG
protein that has been shown to be an important tran-
scriptional repressor of the Ink4a/Arf gene locus [29-31],
which encodes two separate gene products (p16 ink4a
and p14 Arf ) from two distinct reading frames. P16ink4a
inhibits CDK activity and, thereby, blocks entry into the
cell cycle by preventing phosphorylation of the retino-
blastoma protein (Rb) by cyclin D-CDK4/6 complexes.
P14 ARF arrests cell cycle progression and promotes
apoptosis by promoting the stability of p53 [32]. BMI-1
also plays a critical role in the maintenance of stem cells
[33]. Consistent with these observations suggesting an
important oncogenic role for BMI-1, and up-regulated
BMI-1 expression has been demonstrated in numeroushuman cancers [27,28], including bladder cancer [34].
High expression of BMI-1 has been shown to be associ-
ated with poor prognosis in bladder cancer [35].
E2F3, a key regulator of G1/S transition, plays major
roles in regulating both cell proliferations [36]. More re-
cently, several miRNAs, such as miR-34a, miR-20a and
miR-125b have been reported to inhibit cell proliferation
by negatively regulating E2F3 in tumor cells [37-39].
Notably, E2F3 is over-expressed in almost all bladder
cancer and cell lines [40,41], suggesting that E2F3 is im-
portant for human bladder cancer development.
The aim of this study was to investigate the mecha-
nisms underlying the EMT process in bladder cancer.
Our results revealed a close, direct association between
expression of miR-200c, BMI-1, E-cadherin, N-cadherin,
P14, P16 and E2F3 expression, representing a pivotal
cellular axis impacting not only the capacity of bladder
cancer cells to metastasize but also the ability of prolifer-
ation. In this study, we found that down-regulated ex-
pression of miR-200c and up-regulation of its direct
target BMI-1 and E2F3 in bladder cancer tissue and cell
lines. MiR-200c suppressed tumorigenesis through tar-
geting BMI-1 and E2F3.
Methods
Cell lines and cell culture
Human bladder cancer cell lines (UMUC-3 and T24) were
purchased from Guangzhou Jennio Biological Technology
Co., Ltd, Guangzhou, China. All cell lines were maintained
in high glucose DMEM medium (GIBCO, Gaithersburg,
MD, USA) supplemented with 10% fetal bovine serum
(FBS) at 37°C with an atmosphere of 5% CO2 in humidi-
fied air.
Tissue specimens
Clinical tissue samples used in this study were histo-
pathologically and clinically diagnosed at the Affiliated
Hospital of Guangdong Medical College (Zhanjiang,
China) from 2012 to 2014. For the use of these clinical
materials for research purposes, prior patients’ consents
and approval from the Institutional Research Ethics
Committee were obtained.
RNA Isolation and quantitative RT-PCR
Total RNA and miRNA were isolated using the Total RNA
kit (Omega Bio-tek, Inc, Guangzhou, China) and miRNA
kit (Omega Bio-tek, Inc, Guangzhou, China) respectively
followed by cDNA synthesis with 5 ng of total RNA using
the TaqMan miRNA Reverse Transcription Kit (TaKaRa).
BMI-1, E2F3, E-cadherin, N-cadherin, Vimentin, p16INK4a,
and p14ARF expression levels in cells and clinical spe-
cimens were quantified by real-time quantitative PCR
performed with SYBR Premix Ex Taq II (TaKaRa; Dalian,
Liaoning, China). PCR was carried out with a two-step
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control) at 95°C for 30s, followed by 40 cycles of amplifica-
tion at 95°C for 5 s and 56°C for 30s. All results were repre-
sentative of three independent assays, and the expression
levels of miRNAs and mRNAs were expressed as 2-ΔΔCT.
The designed specific primers were listed in Table 1.
Western blot analysis
Western blotting was conducted using standard procedures,
using anti-BMI-1 (40kD, 1:20000, Abcom; Cambridge,
USA), anti E2F3 (37kD, 1:2000, Abcom; Cambridge, USA),
anti-E-cadherin (135kD, 1:1000, Cell Signaling Technology;
Boston, USA), anti-N-cadherin (140kD, 1:1000, Abcom;
Cambridge, USA), anti-Vimentin, anti-p16INK4a (16kD,
1:500, Abcom; Cambridge, USA), anti-p14ARF (14kD,
1:500, Cell Signaling Technology; Boston, USA), or anti-β-
tubulin antibody (55kD, 1:50000, Pure Earth Biotechology
Co. Ltd.; Guangzhou, China, as a loading control), respect-
ively. And then the membrane strips were probed with a
secondary antibody (1:10000, Pure Earth Biotechology Co.
Ltd.), β-tubulin was used as a loading control. Relative
protein levels were quantified by scanning densitometry
(Alpha View SA 3.4.0, ProteinSimple, USA), and the rela-
tive gray value of protein was calculated as band intensity
of protein of interest/band intensity of loading control.
Infection of miRNAs
Vector control (pEZX-MR03, GeneCopoeia; Guangzhou,
China), miR-200c over-expression plasmid (pEZX-MR03,
GeneCopoeia; Guangzhou, China), and miR-200c inhibit
plasmid (CMV- RFP- U6- miRNA inhibitor-PGK-
puromycin, GeneCopoeia; Guangzhou, China) were trans-
fected into 293 T cells, and viral supernatants were
collected 48 h after transfection to infect human bladderTable 1 Sequences for target gene primers for qRT-PCR
Gene Primer sequence 5′-3′ Tm (°C)
RNU6B F: CTCGCTTCGGCAGCACA 59.42
R: AACGCTTCACGAATTTGCGT 55.75
miR-200c F: TAATACTGCCGGGTAATGATGG 58.21
R: TCGTATCCAGTGCAGGGTC 59.72
GAPDH F: TGCACCACCAACTGCTTAG 60.07
R: AGTAGAGGCAGGGATGATGTTC 59.72
Bmi1 F: TGGATCGGAAAGTAAACAAAGAC 56.60
R: TGCATCACAGTCATTGCTGCT 58.01
E2F3 F: TGCCTGACTCAATAGAGAGCCTAC 61.97
R: TCCCATTGTGGTCTTGGTTGT 58.01
E-cadherin F: GAAAGCGGCTGATACTGACC 59.85
R: CGTACATGTCAGCCGCTTC 59.72
Vimentin F: GGGAGAAATTGCAGGAGGAG 59.85
R: AGGTCAAGACGTGCCAGAGAC 61.92cancer cells (UMUC-3, T24). After a 72-hour infection
period, miR-200c-infected cells were seen accounting ap-
proximately 70% in the dish at which point we change the
culture medium containing puromycin at 1 μg/ml for
about 48 h post-transfection.
Luciferase reporter assay
3′-Untranslated region (3′-UTR) reporter plasmids for
miR-200c were constructed via insertion of miR-200c seed
sequence into the XbaI restriction site 3′ to luciferase
gene in the pGL3-control plasmid (Promega, Madison,
WI, USA). Briefly, HEK-293 cells were seeded in 24 well
cell culture clusters (Corning Incorporated; Corning, NY,
USA). When reached 70% confluences, the cells were co-
transfected with hsa-miR-200c/control miRNA and wild/
mutated 3’-UTR of BMI-1, E2F3. After 48 h of transfec-
tion, the cells were harvested for firefly and Renilla lucifer-
ase activity assay. The Renilla luciferase activities were
used to normalize the transfection efficiency.
Cell proliferation assay
Cells (5 × 103) transfected with control vectors, miR-200c
over-expression, and miR-200c inhibitor vector were
plated in 96-well plates (Corning Incorporated; Corning,
NY, USA) for 6 days, separately. The CCK-8 reagent was
added into each well of the 96-well assay plate each day
and incubated for 2 h. The absorbance was measured at
450 nm using a 96-well plate reader.
Colony formation assay
Colony formation assay was performed by a slightly
modified method, briefly, 1000 cells were seeded into
60 mm plastic dishes (Nest Biotechnology, Hong Kong,
China), and cultured with 3 mL DMEM medium supple-
mented with 10% FBS at 37°C under an atmosphere of
5% CO2 in humidified air (UMUC-3 cells were cultured
for 7 days and T24 cells were cultured for 12 days, re-
spectively). The numbers of colonies were counted after
staining with Coomassie Brilliant Blue. All studies were
conducted with 3 replications.
In vitro wound healing (migration) assay
UMUC-3 and T24 cells (5 × 105) were plated in 6-well
plates and cultured until they reached confluence. A dia-
metric scratch was done using a pipette tip followed by
two culture medium changes. Cells were photographed
in several pre-marked spots as 0 h. Multiple photo-
graphs were then taken at 24 h in the same spots for
comparison.
In vitro transwell (invasion and migration) assay
In vitro transwell (invasion) assay was performed by a
modified method, briefly, 3 × 104 cells in 150 μL serum-
free medium supplemented with 1% FBS were seeded
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area, 0.33 cm2; membrane pore size, 8 μm; Corning
Incorporated; Corning, NY, USA) with Matrigel (BD
Biosciences, MA), and 500 μL medium supplemented
with 10% FBS was added into the lower chamber of 24-
well plastic plate. After 24 h of incubation at 37°C, the
cells remained in the upper chamber or on the mem-
brane were removed. Cells adhering to the lower mem-
brane of the inserts were stained with DAPI after which
were captured with confocal microscopy. The numbers
of cells were counted in the images. Transwell (migra-
tion) assay was conducted the same as described above
but not with Matrigel.
Statistical analysis
Each experiment was done at least twice and at least
one duplicate. The results were presented as mean ± SD.
All calculations including statistical analysis were done
by one-way ANOVA (SPSS 18.0). miRNA target predic-
tion and associated mRNA pathway analysis were done
using Ingenuity Pathway Analysis and TargetScan. Dif-
ferences between treatments were assessed using Fisher’s
Least Significant Difference test (LSD (L)). Significant
difference was inferred for P < 0.05 and extremely signifi-
cant difference P < 0.01 and P < 0.001.
Results
miR-200c expression is decreased in bladder cancer
tissues and cell lines
To investigate the potential significance of miR-200c in
the development and progression of bladder cancer, we
firstly examined the expression of the miR-200c in bladder
cancer cell lines and clinical specimens, and found that
miR-200c was ubiquitously expressed at lower levels in a
panel of 4 human bladder cancer cell lines than inFigure 1 miR-200c was down-regulated in bladder cancer tissues and
Cancer tissues and their corresponding adjacent noncancerous tissues (AN
tubule cell line SV-HUC-1 and four bladder cancer cell lines (5637, TCC-SUPcultured immortalized human nephric tubule cell line SV-
HUC-1 (Figure 1B). In parallel, as shown in Figure 1A,
miR-200c expression was found to be markedly decreased
in all 15 collected bladder cancer lesions as compared with
that in paired adjacent non-cancerous bladder tissues.
These data suggested that miR-200c expression was sig-
nificantly suppressed in bladder cancer.
miR-200c suppressed cell invasion, migration and
proliferation in bladder cancer cells
In the attempt to understand the biologic function of
miR-200c, miR-200c was stably transduced into T24 and
UMUC-3 cells through entivirus carrying miR-200c, re-
spectively, to generate T24-miR-200c and UMUC-3-miR-
200c cell lines. RT-PCR was used to confirm the success of
transduction (Figure 2A). Figure 2H showed that over-
expressed miR-200c inhibited invasion of T24 and UMUC-
3 cells using a transwell essay, and decreased migration of
T24 and UMUC-3 cells using wound-healing assay and
transwell assay in miR-200c over-expression cells compared
with control groups (Figure 2E, 2G). As shown in Figure 2B
and 2C, ectopic miR-200c expression slowed down the
proliferation of the bladder cancer cells, as analyzed with
CCK-8 assay. Consisted with cell proliferation results, the
capacities of colony formation of both cells were robustly
compromised by miR-200c transduction as compared with
corresponding control cells (Figure 2D and 2F). Taken
together, these results suggested that over-expressed miR-
200c suppressed the ability of bladder cancer cells to in-
vade, migrate and proliferate in vitro.
Antagonizing miR-200c accelerated cell invasion, migration
and proliferation in bladder cancer cells
To understand the role of endogenous miR-200c in the
modulation of cell invasion, migration and proliferation,cell lines. A: Relative expression of miR-200c in 15 pairs of Bladder
T). B: Different expressions of miR-200c in immortalized human nephric
, T24, UMUC-3).
Figure 2 Up-regulated miR-200c inhibited proliferation, migration and invasion in bladder cancer cells. A: Entivirus carrying miR-200c
plasmid and the control plasmid were persistently co-transfected into UMUC-3 and T24 cells. Measurements by real-time RT-PCR of miR-200c
confirmed our success of transduction and were obviously higher than the control group in both cell lines. B: CCK-8 assays revealed cell growth
differences of indicated cell lines. C: Colony formation assay in T24 and UMUC-3 cells. D: Measurement of in vitro cell migration by “wound-healing”
assay. Representative pictures (left) and quantification (right) for same single spot in indicated cell lines. E: Transwell migration assays in indicated
engineered cell lines. F: Transwell invasion assays in indicated engineered cell lines. Data are presented as mean ± SD from 3 independent experiments.
*P < 0.05; **P < 0.01. ***P < 0.001; DAPI, 4’, 6-diamidino-2-phenylindole.
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as antagonists to silence endogenous miR-200c expression
(Figure 3A). As shown in Figure 3H and 3G, antagonized
miR-200c drastically accelerated invasion, migration ex-
hibited with transwell essay as compared with their corre-
sponding vector-control cells in T24 and UMUC-3 cells,
and the wound-healing assay showed the same tendency.
In parallel, the ability of proliferation was also increased as
showed in Figure 3B, C, D and F, analyzed using CCK-8
assay and colonies formation assay.
miR-200c down-regulated BMI-1 and increases E-cadherin
expression levels in bladder cancer cells
By using TargetScan, a bioinformatic tool for miRNA tar-
get screening, we found that oncogene BMI-1 were tenta-
tive targets of miR-200c (Figure 4A).We also clarified it
with luciferase assay that transfection of miR-200c mimic
oligonucleotides abrogated the expression of luciferase(Figure 4C). However, mutating nucleotides in the seed se-
quence of miR-200c mimic oligonucleotides completely
abolished their binding to the target 3’-UTRs. Indeed, the
expression of BMI-1 inversely correlated with miR-200c
expression in 16 tissue specimens (Figure 4B) at mRNA
levels. Together, these results demonstrate a progressive
diminution of miR-200c expression in bladder cancer
compared with coordinated normal bladder tissues and
suggest a further reduction in expression during bladder
cancer progression, and BMI-1 expression correlates in-
versely with miR-200c expression.
To understand the mechanism underlying the robust
suppressive effect of miR-200c on the invasion and mi-
gration of bladder cancer cells, more mechanism related
research had been done. We asked whether enforced ex-
pression of miR-200c would also affect BMI-1 expres-
sion in bladder cancer cells. As shown in Figure 4E, in
both T24 and UMUC-3 cell lines, western blotting
Figure 3 Down-regulated miR-200c promoted growth and metastasis in bladder cancer cells. A: Antagonizing endogenous miR-200c in
UMUC-3 and T24 cells. Level of miR-200c was measured by real-time PCR and miR-200c was obviously antagonized in the both cell lines. B: CCK-8
assays revealed cell proliferation differences of T24 and UMUC-3 cells. C: Colony formation assay in indicated cell lines. D: Measurement of in vitro cell
migration by wound-healing assay. E: Transwell migration assays in T24 and UMUC-3 cells. F: Transwell invasion cells in T24 and UMUC-3 cells. Data are
presented as mean ± SD from 3 independent experiments. *P < 0.05; **P < 0.01. ***P < 0.001; DAPI, 4’, 6-diamidino-2-phenylindole.
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reduced drastically in miR-200c–transduced cells but
pronouncedly elevated in miR-200c–silenced cells, as com-
pared with those in the corresponding control cells. In
parallel, miR-200c had great impact on the mRNA levels of
these putative targets (Additional file 1: Figure S1). In
consistence with these results, E-cadherin increased in
miR-200c over-expressed cell lines but was down-regulated
in miR-200c–inhibited cells of T24 (Figure 4E). Over-
expressed miR-200c down-regulated production of mesen-
chymal marker N-cadherin and vimentin, but up-regulated
E-cadherin expression in T24 cells (Figure 4E). BMI-1 has
been proved to suppress the transcription of p16 and p14
in many tumors [16,17,40]. We wonder that how will p16
and p14 change after miRNA transfected. As Figure 4E
showed, P16 and P14 were up-regulated in miR-200c over-
expressed cells of T24 and UMUC-3 cells but the opposite
in the miR-200c antagonized cells.miR-200c down-regulated E2F3 in bladder cancer cell
lines
To determine the molecular mechanism of inducing cell
growth arrest related with E2F3, we used 3 open-target
prediction programs (i.e., picTar, TargetScan, and miR-
nada) to predict the targets of miR-200c. E2F3 was one of
the oncogenic genes that were potential miR-200c targets.
The 3’-UTR of E2F3 mRNA contained a complementary
site for the seed region of miR-200c (Figure 4A). To deter-
mine whether E2F3 is the direct target gene for miR-200c,
a dual-luciferase reporter system was employed. The lucif-
erase reporter assay indicated that the luciferase activity of
the reporter containing the E2F3 gene’s wild-type 3’-UTR
decreased (52%) following treatment with miR-200c mimics.
qRT-PCR was applied to determine how the mRNA levels
of E2F3 changed in response to miR-200c transfection
(Additional file 1: Figure S1). Results revealed that the ex-
pression of E2F3 mRNA and protein was inhibited by
Figure 4 miR-200c regulated the growth and metastasis of bladder cancer by directly targeting to BMI-1 and E2F3. A: miR-200c directly
targeted BMI-1. miR-200c directly targeted E2F3. B: Relationship between BMI-1 and miR-200c in the mRNA level. 16 tissue specimens were tested to
measure the relationship between BMI-1 mRNA and miR-200c level, and found inverse correlation between BMI-1 and miR-200c. C and D: luciferase
activity of pGL3-BMI-1-3’-UTR, pGL3-E2F3-3’-UTR reporter in indicated cells cotransfected with indicated oligonucleotides. E: Western blotting of BMI-1,
E-cadherin, N-cadherin, Vimentin, P14, P16, and E2F3 expression in indicated cells. β-tubulin was used as a loading control.
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UMUC-3 cells (Figure 4E). By contrast, the inhibitory ef-
fect of the MiR-200c mimics was abolished in the mutated
construct (Figure 4D). Taken together these data suggest
that miR-200c reduces E2F3 expression by inhibiting
translation and/or causing mRNA instability.
Discussion
The current study has indicated that miR-200c is a
tumor-suppressive miRNA in bladder cancer, and that
oncogene and transcription promoters, namely, BMI-1
and E2F3, are functional targets of miR-200c. Our data
demonstrated that miR-200c is remarkably down-
regulated in bladder cancer cell lines and surgically ex-
cised bladder tumors. In this context, we have found
that experimental up-regulation of miR-200c expression
in bladder cancer cells leads to suppression of BMI-1
and E2F3, and disrupted invasion, migration and prolif-
eration of the bladder cancer cells, whereas completely
silencing miR-200c further up-regulates BMI-1 and E2F3
and promotes progression. Furthermore, inverse correl-
ation between miR-200c level and expression of BMI-1,
as well as tumor progression, is evidenced in our clinical
relevance study. Particularly, miR-200c over-expressionis significantly associated with improved survival in pa-
tients with bladder cancer, further suggesting a tumor-
suppressive function of the molecule.
Interestingly, miR-200c is up-regulated in pancreatic
cancer and the ability of proliferation of which was
strengthen [42]. Moreover, a study by LIU [43] and col-
leagues suggests that the expression levels of miR-200c
in non-small-cell lung cancer [NSCLC] were higher than
those in normal tissues, and high expressions of tumor
miR-200c was associated with a poor survival in NSCLC
patients. On the other hand, however, Chang [18] and
colleagues found that miR-200c inhibits metastasis of
breast cancer cells by targeting HMGB1.
But how could miR-200c mediated the tumor suppres-
sive effects? By miRNA target prediction and dual re-
porter gene, we confirmed oncogene BMI-1 as a directly
target of miR-200c. And up-regulation of miR-200c de-
creased the BMI-1 gene expression, which inhibited the
process of bladder cancer [44]. Chang and Boominathan
L [45,46] and colleagues reported that miR-200c was a
direct target of p53 transcription factor. P53 could in-
hibit cell proliferation through cell cycle arrest [29,30].
In this study we also found that over-expression of miR-
200c caused similar effects that inhibited proliferation. It
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cause p53 suppression, which provided evidence for the
existence of some positive feedbacks [47,48]. In our
study, we up-regulated BMI-1 through down-expression
of miR-200c and found the approximate phenomenon,
increased proliferation. BMI-1 expression inversely cor-
relates with expressions of p14 and p16 in colorectal car-
cinomas [31]. BMI-1 has also been reported as an
oncogene by regulating cell cycle inhibitors, p16 and p14
[49], which our consequences also proved. p16 was iden-
tified as an inhibitor of cyclin-dependent kinase 4 and 6
and thereby leads to hypophosphorylation of pRb [49].
On the other hand, p14ARF prevents the degradation
and inactivation of p53 by binding to MDM-2 [50].
BMI-1, as a molecule of accelerating tumor progress,
will promote proliferation of bladder cancer cells. Our
results clearly demonstrate that ectopic miR-200c in-
hibits cell proliferation in T24 and UMUC-3 bladder
cancer cells. Speaking of inhibition of cell proliferation,
E2F3 maybe one of the targets miR-200c modulated that
played a role in it. E2F3 is a member of the E2F family
that is often dysregulated during tumorigenesis and
over-expressed in a variety of cancers, including bladder
cancer [39]. Recent studies suggest a critical role of E2F3
in gene expression control during the G1/S transition.
Inhibitory antibodies against E2F3 blocked cell entry
into the S phase [51]. In our study, we found that E2F3
was down-regulated in the miR-200c over-expression
bladder cancer cell lines and consequently the prolifera-
tion was inhibited which was proved by CCK-8 assay
and clone formation assay.
Several recent publications have suggested that regula-
tion of the epithelial phenotype contributes to the miR-
200c by acting on the E-cadherin repressors such as
ZEB1/2 [17,52], the predominant target and negative
regulators of miR-200c, through which the capabilities
of invasion and migration of cancer cells was regulated.
In our study, we found the same tendency; miR-200c
directly mediated transcriptional up-regulation of E-
cadherin through translational repression of ZEB1, the
same as in MDAMB-231 cells [53], and down-regulation
of the mesenchymal marker N-cadherin and vimentin.
We also obtained the results of invasion and migration
which were coincident with EMT hallmark E-cadherin.
By conducting the current study, we provide compelling
biologic as well as clinical evidence that in bladder cancer
miR-200c expression is markedly down-regulated, and
that miR-200c acts to suppress the invasion, migration
and proliferation of bladder cancer cells in vitro, suggest-
ing that miR-200c plays a tumor suppressive role in the
cancer type. These findings together indicate a dual role of
miR-200c as either a tumor-promoting or suppressive
miRNA, underscoring the need to define the specific role
of a miRNA in a certain type of cancer. In this context,genetic and micro-environmental cues are believed to be
important to determining whether, and how, a miRNA
molecule functions to promote or to suppress oncogenes.
Thus, it remains important to thoroughly understand the
molecular mechanisms mediating the differential biologic
effects and targets of miR-200c in bladder cancer and
other cancer types.
Our current study has identified invasion, migration and
proliferation regulator BMI-1, proliferation regulator E2F3
which was a transcriptional factor as bonafide targets of
miR-200c. These genes control the characters of invasion,
migration and proliferation and thus BMI-1 have been im-
plicated as proto-oncogenes and E2F3 the transcriptional
factor attractive therapeutic targets against cancer. Over-
expression of BMI-1 is one of the hallmarks of various
cancer types, due to its relatively high amplification fre-
quency and up-regulated expression of its mRNA and pro-
tein in a variety of tumors including bladder cancer,
kidney cancer, and breast cancer.
The research above, on the one hand provide new in-
sights in our need to develop more efficacious therapeutic
approach to improved treatment of bladder cancer. On the
other hand, however, the mechanism via which miR-200c is
down-regulated in bladder cancer remains uninvestigated.Conclusions
Taken together, it would be of great interest to further in-
vestigate whether miR-200c down-regulation in bladder
cancer was attributable to genomic deletion and/or pro-
moter methylation. In summary, on the backdrop that
bladder cancer remains a highly challenging and deadly
malignancy, in addition to searching for novel therapeutic
agents, it is equally important to identify effective bio-
markers for diagnosis and prognosis of bladder cancer. To
this end, our present finding that the level of miR-200c ex-
pression correlates with the clinic pathologic features and
patient survival in bladder cancer makes it a reasonable
candidate biomarker for determination of the prognosis of
the disease. Thus, these findings warrant further investiga-
tion on the potential development of miR-200c-based
prognostic and therapeutic approaches.Additional file
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